Italia markets closed

Rani Therapeutics Holdings, Inc. (RANI)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
4,0300-0,0500 (-1,23%)
Alla chiusura: 04:00PM EDT
4,0800 +0,05 (+1,24%)
Dopo ore: 05:58PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente4,0800
Aperto4,0600
Denaro3,9700 x 100
Domanda4,2100 x 100
Min-Max giorno4,0300 - 4,4400
Intervallo di 52 settimane1,8200 - 8,7500
Volume109.384
Media Volume149.065
Capitalizzazione208,278M
Beta (mensile su 5 anni)0,26
Rapporto PE (ttm)N/D
EPS (ttm)-1,2900
Prossima data utili20 mar 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A10,57
  • GlobeNewswire

    Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

    SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada. The details of the presentation are as follows: A

  • GlobeNewswire

    Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

    - Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an oral

  • GlobeNewswire

    Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

    - Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance - Increased payload of up to 20mg enables potential delivery of 90+ additional drug candidates - SAN JOSE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA